Laurus Labs has signed a memorandum of agreement (MoA) with IIT-Kanpur (IIT-K) to in-license a few gene therapy assets and extend a research grant to the premier institution for advancing the products through pre-clinical development.
The drug manufacturer will also fund the clinical trials and launch the products in India and emerging markets. Additionally, it will establish a GMP (good manufacturing practice) facility at the Techno Park facility of IIT-K, Laurus said on Monday.
The Department of Biological Sciences and Bioengineering (BSBE) at IIT-K has been working on a gene therapy for the last few years and have developed a few gene therapy assets along with technology for novel Adeno Associated Virus (AAV) vectors. It has filed IPs around these products and a few additional patent applications will be filed in due course, the company said.
